Mirae Asset Global Etfs Holdings Ltd. Candel Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $47.1 Billion
- Q2 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 21,520 shares of CADL stock, worth $119,005. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,520
Previous 16,748
28.49%
Holding current value
$119,005
Previous $94,000
14.89%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CADL
# of Institutions
84Shares Held
15.3MCall Options Held
570KPut Options Held
203K-
Acorn Capital Advisors, LLC New York, NY2.58MShares$14.3 Million8.54% of portfolio
-
Northpond Ventures, LLC1.94MShares$10.7 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.79MShares$9.89 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.62MShares$8.97 Million0.59% of portfolio
-
Geode Capital Management, LLC Boston, MA904KShares$5 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $160M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...